Female InfertilityNCT07740187
A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility
A study testing WeNatal For Her Supplement in people with Female Infertility and Reproductive Health, run by WeNatal at 1 site in United States.
Trial summary
This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Female Infertility, Reproductive Health, Fertility
- What is being tested?
- WeNatal For Her Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Apr 2025to 12 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be female.
- Be aged 18-45.
- In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue
- Bloating
- Breast tenderness
- Irritability or mood swings.
Show all 13Show fewer
- Currently trying to conceive.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Not planning on introducing any products or any new forms of prescription medication or supplements that target female fertility for the study duration.
- Has a regular menstrual cycle between 21 and 35 days in length and is able to predict the dates of their upcoming periods.
- Resides in the United States.
- Not currently partaking in another research study and will not be partaking in any other research study for the next three menstrual cycles and at any point during this study's duration.
- Willing to avoid all other prenatal vitamins for the duration of this study.
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are currently pregnant or breastfeeding.
- Anyone taking anticoagulant or "blood thinning" medication.
- Anyone taking bisphosphonates or other prescription medications for osteoporosis.
- Anyone taking chemotherapy medication.
Show all 14Show fewer
- Anyone diagnosed with hemochromatosis or elevated iron levels.
- Anyone who drinks heavily (i.e. eight or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Anyone unwilling to follow the study protocol.
- Anyone with a history of substance abuse.
- Anyone who is currently a smoker or has been a smoker in the past three months.
- Anyone who has stopped using hormonal birth control less than six months prior to starting the study.
- Anyone previously diagnosed with premenstrual dysphoric disorder (PMDD), endometriosis, or any cancer of the reproductive system.
- Anyone who is peri- or post-menopausal.
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal.
The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.
- Being tested
- WeNatal For Her Supplement
- Medical subject headings
- Infertility, Female
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WeNatal For Her SupplementDietary supplement
All 40 participants take three capsules of the WeNatal For Her supplement daily in the morning with their first meal for three menstrual cycles.
| Study group | Role | What they receive |
|---|---|---|
| WeNatal For Her Supplement | Experimental | Not described Receives: Dietary Supplement: WeNatal For Her Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Anti-Müllerian Hormone (AMH)
Blood test measurement of serum AMH level to assess ovarian reserve
Measured: Baseline and Day 2-5 of Cycle 3
Change in Follicle-Stimulating Hormone (FSH)
Blood test measurement of serum FSH level
Measured: Baseline and Day 2-5 of Cycle 3
Change in Estradiol
Blood test measurement of serum Estradiol level
Measured: Baseline and Day 2-5 of Cycle 3
Change in Progesterone
Blood test measurement of serum Progesterone level
Measured: Baseline and Day 2-5 of Cycle 3
Change in Testosterone
Blood test measurement of serum Testosterone level
Measured: Baseline and Day 2-5 of Cycle 3
Change in 25-hydroxy Vitamin D
Blood test measurement of serum 25-hydroxy Vitamin D level
Measured: Baseline and Day 2-5 of Cycle 3
Change in Serum Iron
Blood test measurement of serum iron level
Measured: Baseline and Day 2-5 of Cycle 3
Change in Thyroid Stimulating Hormone (TSH)
Blood test measurement of serum TSH level
Measured: Baseline and Day 2-5 of Cycle 3
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Blood test measurement of serum hs-CRP level
Measured: Baseline and Day 2-5 of Cycle 3
Secondary outcomes (5)
Change in Self-Reported Reproductive Health
Assessed via self-reported questionnaire measuring participant perceptions of reproductive health
Measured: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Energy Levels
Assessed via self-reported questionnaire measuring participant perceptions of energy levels
Measured: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Mood
Assessed via self-reported questionnaire measuring participant perceptions of mood
Measured: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Breast Tenderness
Assessed via self-reported questionnaire measuring participant perceptions of breast tenderness
Measured: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Overall Well-Being
Assessed via self-reported questionnaire measuring participant perceptions of overall well-being
Measured: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start15 Apr 2025
- Primary completion12 Feb 2026
- Study completion12 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Female InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- WeNatal
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740187
- Sponsor's protocol ID
- 20729
- Other IDs
- legacy-20729
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility
- ClinicalTrials.gov ID
- NCT07740187
- Acronym / sponsor ID
- 20729
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- WeNatalIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 15 Apr 2025 (actual)
- Primary completion
- 12 Feb 2026 (actual)
- Study completion
- 12 Feb 2026 (actual)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal.
The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| WeNatal For Her Supplement | Experimental | Dietary Supplement: WeNatal For Her Supplement |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (13 listed)
- Be female.
- Be aged 18-45.
- In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue
- Bloating
- Breast tenderness
Key exclusion criteria (14 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are currently pregnant or breastfeeding.
- Anyone taking anticoagulant or "blood thinning" medication.
- Anyone taking bisphosphonates or other prescription medications for osteoporosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WeNatal For Her SupplementAll 40 participants take three capsules of the WeNatal For Her supplement daily in the morning with their first meal for three menstrual cycles. | Dietary supplement | WeNatal For Her Supplement |
Primary outcome
Change in Anti-Müllerian Hormone (AMH)
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum AMH level to assess ovarian reserve
Change in Follicle-Stimulating Hormone (FSH)
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum FSH level
Change in Estradiol
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum Estradiol level
Change in Progesterone
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum Progesterone level
Change in Testosterone
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum Testosterone level
Change in 25-hydroxy Vitamin D
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum 25-hydroxy Vitamin D level
Change in Serum Iron
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum iron level
Change in Thyroid Stimulating Hormone (TSH)
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum TSH level
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Time frame: Baseline and Day 2-5 of Cycle 3
Blood test measurement of serum hs-CRP level
5 secondary outcomes
Change in Self-Reported Reproductive Health
Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Energy Levels
Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Mood
Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Breast Tenderness
Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Change in Self-Reported Overall Well-Being
Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
Related trials for Female Infertility
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
RecruitingObservational study
Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms
Adenomyosis of Uterus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WeNatal For Her Supplement in people with Female Infertility and Reproductive Health, run by WeNatal at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Anti-Müllerian Hormone (AMH) (time frame: Baseline and Day 2-5 of Cycle 3). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.